|1.||Dwek, Raymond A: 2 articles (02/2004 - 04/2002)|
|2.||Gu, Y: 1 article (01/2015)|
|3.||Harvey, D J: 1 article (01/2015)|
|4.||McCauley, J W: 1 article (01/2015)|
|5.||Zitzmann, N: 1 article (01/2015)|
|6.||Miller, J L: 1 article (01/2015)|
|7.||Hussain, S: 1 article (01/2015)|
|8.||Rosenthal, P B: 1 article (01/2015)|
|9.||García Fernández, José M: 1 article (11/2009)|
|10.||Luan, Zhuo: 1 article (11/2009)|
04/01/2002 - "Additionally, in a mouse model of lethal challenge by JEV infection, oral delivery of NN-DNJ reduced the mortality rate. "
04/01/2002 - "This inhibitory effect appeared to influence DEN-2 infection more than JEV infection, since lower concentrations of NN-DNJ substantially blocked DEN-2 replication. "
04/01/2002 - "In the presence of NN-DNJ, JEV and DEN-2 infections were suppressed in a dose-dependent manner. "
04/01/2002 - "Here we investigated the effects of one such inhibitor, N-nonyl-deoxynojirimycin (NN-DNJ), a 9-carbon alkyl iminosugar derivative, on infection by Japanese encephalitis virus (JEV) and dengue virus serotype 2 (DEN-2). "
10/12/1999 - "We have shown previously that the NN-DNJ-induced misfolding of one of the hepatitis B virus (HBV) envelope glycoproteins prevents the formation and secretion of virus in vitro and that this inhibitor alters glycosylation and reduces the viral levels in an animal model of chronic HBV infection. "
|2.||Gaucher Disease (Gaucher's Disease)
11/23/2009 - "The chaperone effects of the sp2 iminosugar were generally stronger than those observed for NN-DNJ; this suggests that these compounds are promising candidates for clinical treatment of GD patients with a broad range of beta-Glu mutations, especially for neuronopathic forms of Gaucher disease."
11/26/2002 - "The NN-DNJ chaperone also increases WT beta-Glu activity, but not that of L444P, a less prevalent Gaucher disease variant. "
11/26/2002 - "We report herein that the addition of subinhibitory concentrations (10 microM) of N-(n-nonyl)deoxynojirimycin (NN-DNJ) to a fibroblast culture medium for 9 days leads to a 2-fold increase in the activity of N370S beta-Glu, the most common mutation causing Gaucher disease. "
|4.||Human Influenza (Influenza)
01/01/2015 - "Consistent with its action as an α-glucosidase inhibitor, NN-DNJ treatment resulted in an altered glycan processing of influenza haemagglutinin (HA) and neuraminidase (NA), confirmed by MS. NN-DNJ treatment was found to reduce the cell surface expression of the H3 subtype HA. "
01/01/2015 - "Here the effect and mechanism of two iminosugar α-glucosidase inhibitors, N-butyl-deoxynojirimycin (NB-DNJ) and N-nonyl-deoxynojirimycin (NN-DNJ), on human influenza A viruses was examined. "